Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds
Ghent, Belgium, and Dresden, Germany - 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine...
Confo Therapeutics receives €1.7 million grant from VLAIO to progress novel GPCR-modulating compounds for an orphan indication
Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the...
ADC Therapeutics Expands to Third Program Using Synaffix’s ADC Platform under Existing Agreement
AMSTERDAM, NETHERLANDS – May 28, 2019 – Synaffix B.V., a Dutch biotechnology company focused on the advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that ADC Therapeutics has triggered a...
Cristal Therapeutics to present data at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting on lead clinical candidate CPC634 in patients with solid tumors
• Three poster presentations will be given by the company and its collaborators Cristal Therapeutics • Florence Atrafi, MD, a clinical investigator on the phase 1 NAPOLY study, has received a prestigious ASCO Merit Award in recognition of her abstract that highlights...
Confo Therapeutics raises €30 million in Series A financing
Round led by BioGeneration Ventures and co-led by Wellington Partners, with investments by Fund+, Perceptive Advisors and existing investors Ghent, Belgium, 7 May 2019 – Confo Therapeutics, an emerging drug discovery company, today announces the completion of a €30...
Synaffix Announces License Agreement worth up to $125 million with Leading Chinese ADC Developer, Shanghai Miracogen
AMSTERDAM, NETHERLANDS – April 10, 2019 – Synaffix B.V., a Dutch biotechnology company exclusively focused on continued advancement of its clinical-stage antibody-drug conjugate (ADC) technology for the development of best-in-class ADCs, announces that it has entered...
Synaffix ADC Technology Enters the Clinic as Collaboration with ADC Therapeutics Advances
Lausanne, Switzerland, January 16, 2019 – ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I...
Synaffix Announces License Agreement with Mersana Therapeutics for the Use of its GlycoConnect™ Site-Specific ADC Technology
AMSTERDAM, NETHERLANDS – January 4, 2019 – Synaffix B.V. announced today it has entered into a license agreement with Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates...
BioGeneration Ventures’ portfolio company Staten Biotechnology announces collaboration with Novo Nordisk
BioGeneration Ventures (BGV) is pleased to announce that its portfolio company Staten Biotechnology B.V. and Novo Nordisk A/S have entered into a collaboration and exclusive option agreement. Under the collaboration agreement, Staten will continue to develop its lead...
Press Release NorthSea Therapeutics: Icosabutate latest data shows direct and potent anti-fibrotic effect in both differentiated rodent NASH models and human stellate cells.
Results to be presented at the AASLD congress 2018, 9-13 November In a biopsy-confirmed fibrotic ob/ob NASH mouse model, icosabutate reduced hepatic fibrosis in association with a 45% decrease in myofibroblast content in pre- versus post-treatment liver biopsies In a...